Diabetic Neuropathic Pain Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

List of Tables

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic neuropathic pain market through 2031.

Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.

Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs

Key Highlights

Forecasts includes the 7MM
Forecasts covers from 2021-2031
In the 7MM, the diagnosed prevalent cases of DNP will increase from 4,447,050 cases in 2021 to 5,157,455 cases in 2031, at an AGR of 1.60%.
The current DNP treatment landscape includes many established analgesics that provide symptomatic relief. The main drug classes that are used l include tricyclic antidepressants (TCAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), alpha-2-delta ligands (gabapentinoids), sodium channel blockers, and topical treatments.
The DNP market will exhibit moderate growth between 2021 and 2031, driven by the entry of four pipeline agents.
Engensis will be welcomed by patients as the underlying pathophysiology of DNP will be targeted, rather than symptomatic treatment.

Scope

Overview of diabetic neuropathic pain, including epidemiology, symptoms, diagnosis, and disease management.
Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for diabetic neuropathic pain treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathic pain therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global diabetic neuropathic pain therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Product Code: GDHC264PIDR

1 Diabetic Neuropathic Pain: Executive Summary

1.1 DNP market will grow to $3.0 billion
1.2 Key players will struggle to maintain their competitive position
1.3 While outlook in DNP improves, opportunities remain to improve patient outcomes
1.4 Novel late-stage pipeline drugs will be a key driver of growth
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
- 4.4.1 Sources used
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Total prevalent cases of DNP
- 4.4.4 Diagnosed prevalent cases of DNP
- 4.4.5 Diagnosed prevalent cases of DNP by DSPN and non-DSPN
- 4.4.6 p-DPN among diagnosed prevalent cases of T1D and T2D
4.5 Epidemiological forecast for total prevalent cases of DNP (2021-31)
- 4.5.1 Total prevalent cases of DNP
- 4.5.2 Age-specific total prevalent cases of DNP
- 4.5.3 Sex-specific total prevalent cases of DNP
- 4.5.4 Diagnosed prevalent cases of DNP
- 4.5.5 Diagnosed prevalent cases of DNP by DSPN and Non-DSPN
- 4.5.6 p-DPN among diagnosed prevalent cases of T1D and T2D
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis overview
5.2 Treatment overview
5.3 Other KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Development of therapies with an improved efficacy profile
7.3 Development of therapies with improved safety and tolerability profile
7.4 Development of a curative or disease-modifying agent
7.5 Improving physician and public recognition of DNP

8 R&D Strategies

8.1 Overview
- 8.1.1 Development of analgesics with novel MOAs
- 8.1.2 Patient stratification
8.2 Clinical trials design
- 8.2.1 Clinical endpoints
- 8.2.2 High failure rate in DNP clinical trials
- 8.2.3 Patient recruitment

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
- 13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologist
- 13.6.5 Vice President of Disease Analysis and Intelligence
- 13.6.6 Global Head and EVP of Healthcare Operations and Strategy
Contact Us

Product Code: GDHC264PIDR

List of Tables

Table 1: DNP: key metrics in the 7MM
Table 2: Classification of diabetic neuropathies
Table 3: Risk factors and comorbid conditions associated with DNP
Table 4: Treatment Guidelines for DNP
Table 5: DNP market - global drivers and barriers, 2021-2031
Table 6: Key events impacting sales for DNP in the US, 2021-2031
Table 7: DNP market - drivers and barriers in the US, 2021-2031
Table 8: Key events impacting sales for DNP in the 5EU, 2021-2031
Table 9: DNP market - drivers and barriers in the 5EU, 2021-2031
Table 10: Key events impacting sales for DNP in Japan, 2021-2031
Table 11: DNP market - drivers and barriers in Japan, 2021-2031
Table 12: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Global sales forecast by country for DNP in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in DNP during the forecast period
Figure 3: Competitive assessment of the pipeline drugs benchmarked against the SOC, Lyric

Diabetic Neuropathic Pain Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Description

Table of Contents

List of Tables

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Diabetic Neuropathic Pain: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Tables

List of Tables

List of Figures

List of Figures